LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

Contributed by: Business Wire

Logo

Tags

Mental Health

Surgery

Medical Devices

General Health

Public Policy/Government

Hospitals

Science

Clinical Trials

FDA

Cardiology

Biotechnology

Health

Health Insurance

Other Science

Research

White House/Federal Government

Other Health

LivaNova PLC

More Like This

CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy

LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day